D-125potassium

According to the FDA label: INDICATIONS Skin eruptions, swollen joints.

90,693 adverse event reports submitted to the FDA (1999–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with D-125 in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
D-125 adverse event reports by reporter sex
SexReports
Female53,154
Male32,292
Unknown75

By Age Group

View age group data as a table
D-125 adverse event reports by reporter age group
Age groupReports
0-171,187
18-342,207
35-495,612
50-6417,078
65-7418,192
75+18,208

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included D-125. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
D-125 adverse event reports by reported outcome
OutcomeReports
Hospitalization41,882
Other Serious37,581
Non-Serious22,617
Death13,377
Life-Threatening5,662
Disability2,142

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for D-125. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
D-125 adverse event reports by year
YearReports
19994
20032
2004902
20051,825
20061,348
20071,687
20082,434
20092,665
20102,190
20112,593
20123,573
20132,094
20142,507
20153,973
20164,748
20174,844
20185,827
20195,712
20205,711
20216,032
20226,679
20236,708
20247,515
20257,526
2026 (partial)1,594

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with D-125

In FDA adverse event reports that mention D-125, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026